Clinical Study

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma

Table 4

Univariate and multivariate analysis of disease control rate.

Univariate analysis

Disease control rate

All Patients 23.2% (95% CI:18.9%–27.5%)

SexMale24%P  = .6
Female22%

Age (years)0–3924%P  = .2
40–5927%
60+16%

HistologyLeiomyosarcoma19%P  =  .2
Synovial sarcoma34%P  = .07
Liposarcoma38%P  =  .03
Other19%

DiseaseLocally advanced18%P  = .1
Metastatic—single organ29%
Metastatic—multiple organs17%

Sites of metastasesInvolved versus uninvolved
Lung19% versus 29%P  =  .04
Liver27% versus 22%P  = .4
Bone23% versus 23%P  =  1.0

ChemotherapySingle agent/Phase I21%P  = .02
Combination36%

Chemo RegimenSA Doxorubicin27%
SA Ifosfamide21%
Other SA22%
Phase I trial9%
Dox/Ifos combination38%
Other combination34%

Multivariate analysis

Relative likelihood of disease control (95% CI)Significance

Pathology type
 Liposarcoma versus other 2.51.2–5.1P  =  .02
 Synovial versus other 2.31.2–4.5P  = .02

Sites of disease
 Lungs Involved 0.60.3–1.0P  =  .04

 Not involved 1.0
Chemotherapy
 Single Agent/Phase 1 Combination 1.01.2–4.4P  =  .01
2.3

SA: single agent, Dox/ Ifos: Doxorubicin/Ifosfamide.